Mahé Isabelle
@isabellemahe1
Cardiovascular Disease and Internal Medicine in @univ_paris_cite @APHP @INNOVTE1
You might like
A recent study found that halving the dose of blood thinners after six months provided similar protection from blood clots in people with cancer while lowering the risk of bleeding complications. brnw.ch/21wWoHN @aakonc @crenshawseeds @isabellemahe1
@isabellemahe1 on Reduced Dose Apixaban for Cancer-Associated VTE: API-CAT Trial Results @SaadMahmoodMD hemostasistoday.com/insight/isabel… #APICATStudy #Apixaban #VTE #MedEd #MedX #CancerAssociatedThrombosis #CardioOncology #DOACs #Health #Hematology #Hemostasis #HemostasisToday #Medicine…
#AQUATICtrial 🇫🇷: In chronic coronary syndrome pts at high 🫀atherothrombotic risk on long-term oral anticoagulation (OAC), adding ASA ↑ CV events (HR 1.53), death (HR 1.72) & major bleeding (HR 3.35) without benefit. OAC alone safer. Published in @NEJM nejm.org/doi/full/10.10…
🚨 *St Francis Heart Center, NY CardioOncology Journal Club* @isabellemahe1 (@univ_paris_cite) joined us to discuss API-CAT trial: whether among active cancer patients with VTE, tx with a ⬇️ dose Apixaban prevents recurrent VTE, ⬇️ bleeding🩸: opci.live/opci-lives/ext…
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé / Prof. Francis Couturaud youtu.be/RXttWKQ-sM4?si… @isabellemahe1 and @FCouturaud discuss the use of reduced-dose NOAC treatment for extended treatment of VT, based upon their APICAT and RENOVE trials.
youtube.com
YouTube
Extended reduced-dose DOAC: APICAT / RENOVE - Prof. Isabelle Mahé /...
Isabelle Mahé (@isabellemahe1) Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis @NEJM @MarcCarrier1 @SilvyLaporte @isth hemostasistoday.com/science/isabel… #APICATStudy #Apixaban #MedEd #MedX #CancerAssociatedThrombosis #Health #Hematology…
How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! @RPTHjournal @isth @ESC_Journals doi.org/10.1016/j.rpth…
How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! @RPTHjournal doi.org/10.1016/j.rpth…
Study API-CAT: Low-dose apixaban proved noninferior to full-dose for extended #VTE prevention in active cancer—with significantly less bleeding. Practice-changing. bit.ly/3E4UxFk #ACC25 #Oncology @isabellemahe1 @DSadlerMD @SimonNoble @NEJM
💊 Discontinuation of #VKA in patients with life-limiting disease ⬇️ 📌 Among 18,000+ 🇳🇱 VKA users, >80% continued anticoagulant until 1 month before death 📌 Similar rates of bleeding and thromboembolism during and after VKA discontinuation 🆓👉 thieme-connect.de/products/ejour…
Study API-CAT: Extended low-dose #Apixaban (2.5 mg BID) is noninferior to full-dose for #VTE prevention in cancer—with less bleeding. A potential practice-changer. bit.ly/4jjl4h5 @isabellemahe1 #ACC25 #VTE #Oncology
In the API-CAT trial involving patients with active cancer and venous thromboembolism, extended anticoagulation with reduced-dose apixaban was noninferior to full-dose apixaban for preventing recurrent thromboembolic events. Full trial results and Research Summary:…
Original Article: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT) nej.md/41YkRZK Editorial: Cancer-Associated Venous Thromboembolism — Beyond 6 Months nej.md/4iB6wcA #Cardiology
NEJM | API-CAT 💊💊 Apixaban 2,5 mg x2/j ≈ 5 mg x2/j après 6 mois chez patients #cancer & #MTEV 🟰Incidence récidive : 2,1% vs 2,6% N. 🩸Moins de saignement: 12,1 vs 15,6 S ➡️ Non infériorité + meilleur profil de tolérance nejm.org/doi/full/10.10… @isabellemahe1 @OncoAlert
New in the April 10, 2025, issue of NEJM: Apixaban for Cancer-Associated Venous Thromboembolism (API-CAT) nej.md/41YkRZK Stroke Due to Occlusion of Medium or Distal Vessels (DISTAL) nej.md/4jYWV0z EVT for Stroke Due to Medium-Vessel Occlusion (ESCAPE-MeVO…
New Paper Alert: Reduced-Dose Apixaban Found Effective for Extended Treatment of Cancer-Associated VTE @isabellemahe1 @MarcCarrier1 @MayeurDidier @juanjolopezn @HRobertEbadi oncodaily.com/oncolibrary/re… #AnticoagulantTherapy #Apixaban #CancerCare #MedX #MedEd #OncoDaily #Oncology…
United States Trends
- 1. #Worlds2025 46.3K posts
- 2. Doran 19K posts
- 3. #T1WIN 29.4K posts
- 4. Good Sunday 47K posts
- 5. Faker 33.1K posts
- 6. Sam Houston 1,622 posts
- 7. Oregon State 4,750 posts
- 8. #T1fighting 3,621 posts
- 9. Vergil 8,807 posts
- 10. Boots 30K posts
- 11. Option 2 4,360 posts
- 12. Lubin 5,922 posts
- 13. #Toonami 2,731 posts
- 14. Keria 11.4K posts
- 15. Hyan 1,490 posts
- 16. Frankenstein 127K posts
- 17. Louisville 14.5K posts
- 18. UCLA 7,841 posts
- 19. #GoAvsGo 1,607 posts
- 20. Oilers 5,382 posts
Something went wrong.
Something went wrong.